|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Extraintestinal manifestations in inflammatory bowel disease显示文摘Inflammatory bowel diseases (IBD) can be really considered to be systemic diseases since they are often associated with extraintestinal manifestations,complications, and other autoimmune disorders. Indeed,physicians who care for patients with ulcerative colitis and Crohn's disease, the two major forms of IBD, face a new clinical challenge every day, worsened by the very frequent rate of extraintestinal complications. The goal of this review is to provide an overview and an update on the extraintestinal complications occurring in IBD.Indeed, this paper highlights how virtually almost every organ system can be involved, principally eyes, skin,joints, kidneys, liver and biliary tracts, and vasculature (or vascular system) are the most common sites of systemic IBD and their involvement is dependent on different mechanisms. | Silvio Danese Stefano Semeraro Alfredo Papa Italia Roberto Franco Scaldaferri Giuseppe Fedeli Giovanni Gasbarrini Antonio Gasbarrini | 2005 | World Journal of Gastroenterology2005，11，46： | 24 |
| 2 | Role and mechanisms of action of escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update显示文摘Ulcerative colitis(UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the 'forgotten organ', Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle(Ec N) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor®(Ardeypharm Gmb H, Herdecke, Germany and Ec N, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of Ec N 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of Ec N. | Franco Scaldaferri Viviana Gerardi Francesca Mangiola Loris Riccardo Lopetuso Marco Pizzoferrato Valentina Petito Alfredo Papa Jovana Stojanovic Andrea Poscia Giovanni Cammarota Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，24： | 19 |
| 3 | Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents显示文摘 | Alfredo Papa Carla Felice Manuela Marzo Gianluca Andrisani Alessandro Armuzzi Marcello Covino Giammarco Mocci Daniela Pugliese Italo De Vitis Antonio Gasbarrini Gian Lodovico Rapaccini Luisa Guidi | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 4 | Hyaluronan scaffolds via diglycidyl ether crosslinking: Toward improvements in composition and performance显示文摘 | Annalisa La Gatta Chiara Schiraldi Agata Papa Antonella D’Agostino Marcella Cammarota Alfredo De Rosa Mario De Rosa | 2013 | Carbohydrate Polymers2013，，2： | 1 |
| 5 | Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year显示文摘 | Luisa Guidi Manuela Marzo Gianluca Andrisani Carla Felice Daniela Pugliese Giammarco Mocci Olga Nardone Italo De Vitis Alfredo Papa Gianlodovico Rapaccini Franca Forni Alessandro Armuzzi | 2014 | Digestive and Liver Disease2014，，11： | 1 |
| 6 | Venous thromboembolism in patients with inflammatory bowel disease:Focus on prevention and treatment显示文摘Inflammatory bowel disease(IBD)patients have an increased risk of venous thromboembolism(VTE),which represents a significant cause of morbidity and mortality.The most common sites of VTE in IBD patients are the deep veins of the legs and pulmonary system,followed by the portal and mesenteric veins.However,other sites may also be involved,such as the cerebrovascular and retinal veins.The aetiology of VTE is multifactorial,including both inherited and acquired risk factors that,when simultaneously present,multiply the risk to the patient.VTE prevention involves correcting modifiable risk factors,such as disease activity,vitamin deficiency,dehydration and prolonged immobilisation.The role of mechanical and pharmacological prophylaxis against VTE using anticoagulants is also crucial.However,although guidelines recommend thromboprophylaxis for IBD patients,this method is still poorly implemented because of concerns about its safety and a lack of awareness of the magnitude of thrombotic risk in these patients.Further efforts are required to increase the rate of pharmacological prevention of VTE in IBD patients to avoid preventable morbidity and mortality. | Alfredo Papa Viviana Gerardi Manuela Marzo Carla Felice Gian Lodovico Rapaccini Antonio Gasbarrini | 2014 | World Journal of Gastroenterology2014，20，12： | 1 |
| 7 | What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?显示文摘The use of biological agents and immunomodulators for inflammatory bowel disease(IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review. | Gianluca Andrisani Alessandro Armuzzi Manuela Marzo Carla Felice Daniela Pugliese Alfredo Papa Luisa Guidi | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，3： | 0 |
| 8 | Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients显示文摘Coronavirus disease 2019(COVID-19)has several extrapulmonary symptoms.Gastrointestinal(GI)symptoms are among the most frequent clinical manifestations of COVID-19,with severe consequences reported in elderly patients.Furthermore,the impact of COVID-19 on patients with pre-existing digestive diseases still needs to be fully elucidated,particularly in the older population.This review aimed to investigate the impact of COVID-19 on the GI tract,liver,and pancreas in individuals with and without previous digestive diseases,with a particular focus on the elderly,highlighting the distinctive characteristics observed in this population.Finally,the effectiveness and adverse events of the anti-COVID-19 vaccination in patients with digestive disorders and the peculiarities found in the elderly are discussed. | Alfredo Papa Marcello Covino Sara Sofia De Lucia Angelo Del Gaudio Marcello Fiorani Giorgia Polito Carlo Romano Settanni Andrea Piccioni Francesco Franceschi Antonio Gasbarrini | 2023 | World Journal of Gastroenterology2023，29，26： | 0 |
| 9 | Orphan patients with inflammatory bowel disease-when we treat beyond evidence显示文摘Inflammatory bowel disease(IBD)is a chronic condition that requires continuous medical treatment.To date,the medical management of patients with moderatelyto-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs.Such therapies are licenced after passing through three phases of randomized controlled trials(RCTs),and are subsequently adopted in clinical practice.However,the real-life population of IBD patients who require these therapies can significantly differ from those included in RCTs.As a matter of fact,there is a number of exclusion criteria–nearly ubiquitous in all RCTs–that prevent the enrolment of specific patients:Chronic refractory pouchitis or isolated proctitis in ulcerative colitis,short-bowel syndrome and stomas in Crohn’s disease,ileorectal anastomosis in both ulcerative colitis and Crohn’s disease,and elderly age are some representative examples.In this frontier article,we aim to give an overview of current literature on this topic,in order to address the main knowledge gaps that need to be filled in the upcoming years. | Giuseppe Privitera Daniela Pugliese Loris Riccardo Lopetuso Franco Scaldaferri Alfredo Papa GianLodovico Rapaccini Antonio Gasbarrini Alessandro Armuzzi | 2021 | World Journal of Gastroenterology2021，27，47： | 0 |
| 10 | Infliximab does not increase colonic cancer risk associated to murine chronic colitis显示文摘AIM To explore the influence of Infliximab(IFX) on cancer progression in a murine model of colonic cancer associated to chronic colitis.METHODS AOM/DSS model was induced in C57BL/6 mice. Mice were injected with IFX(5 mg/kg) during each DSS cycle while control mice received saline. Body weight, occult blood test and stool consistency were measured to calculate the disease activity index(DAI). Mice were sacrificed at week 10 and colons were analyzed macroscopically and microscopically for number of cancers and degree of inflammation. MTT assay was performed on CT26 to evaluate the potential IFX role on metabolic activity and proliferation. Cells were incubated with TNF-α or IFX or TNF-α plus IFX, and cell vitality was evaluated after 6, 24 and 48 h. The same setting was used after pre-incubation with TNF-α for 24 h.RESULTS IFX significantly reduced DAI and body weight loss in mice compared with controls, preserving also colon length at sacrifice. Histological score was also reduced in treated mice. At macroscopic analysis, IFX treated mice showed a lower number of tumor lesions compared to controls. This was confirmed at microscopic analysis, although differences were not statistically significant. In vitro, IFX treated CT26 maintained similar proliferation ability at MTT test, both when exposed to IFX alone and when associated to TNF-α.CONCLUSION IFX did not increase colonic cancer risk in AOM-DSS model of cancer on chronic colitis nor influence directly the proliferation of murine colon cancer epithelial cells. | Loris R Lopetuso Valentina Petito Tiziano Zinicola Cristina Graziani Viviana Gerardi Vincenzo Arena Maria Emiliana Caristo Andrea Poscia Giovanni Cammarota Alfredo Papa Valerio Cufino Alessandro Sgambato Antonio Gasbarrini Franco Scaldaferri | 2016 | World Journal of Gastroenterology2016，22，44： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员